In vitro, at clinically achievable concentrations, PTK787 can inhibit VEGF-induced cell proliferation, migration, growth, and survival, and overcome drug resistance of MM cells (cell lines and patient-derived) in the presence of Dex and IL-6 and/or cultured with BMSCs [160]. This evidence concerns the gene VEGFA and Miyoshi myopathy.